Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer

NCT00321620 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00321620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00321620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2006
Completion date
February 24, 2012
Enrollment
1,904 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases